Gastric & esophageal cancer

Oncology· 7 reviewed drugs· 31081 cited findings behind them

What the regulatory reviews cover

Regulatory review documents in this library for Gastric & esophageal cancer include Vyloy, Teysuno, and Lonsurf. Vyloy is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive, with a Median OS of 14.39 compared to 12.16 for Placebo + CAPOX. Teysuno is indicated for metastatic gastric cancer and advanced gastric cancer, showing a Median overall survival of 30 months. Lonsurf, indicated for metastatic colorectal cancer, has a Median OS of 7.1.

It is important to note that these drugs were studied in different trials, and therefore the figures presented are not head-to-head comparisons. Each drug's efficacy and safety profile should be considered within the context of its specific clinical trials and indications.

The drugs — one cited result each

Keytruda Merck & Co., Inc.	24441 cited findings on the drug page →
Taxotere Sanofi	3154 cited findings on the drug page →
Vyloy Astellas Pharma Inc.	Median OS: 14.39 Astellas Pharma Inc. — Vyloy EMA EPAR public assessment repo, p.133
Loqtorzi Topalliance Biosciences	763 cited findings on the drug page →
Xeloda Cheplapharm	742 cited findings on the drug page →
Lonsurf Otsuka Holdings Co., Ltd.	Median OS: 7.1 TAIHO ONCOLOGY — Lonsurf FDA Review, p.28
Teysuno Nordic B V	Median overall survival: 30 months Nordic B V — Teysuno EMA EPAR variation assessment report (E, p.7

Different drugs were studied in different trials — these figures are not head-to-head comparisons.

Explore the full evidence

Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →

Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.